These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231 [TBL] [Abstract][Full Text] [Related]
3. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Jun M; James MT; Ma Z; Zhang J; Tonelli M; McAlister FA; Manns BJ; Ravani P; Quinn RR; Wiebe N; Perkovic V; Wilton SB; Winkelmayer WC; Hemmelgarn BR; Am J Kidney Dis; 2017 Jun; 69(6):734-743. PubMed ID: 27998624 [TBL] [Abstract][Full Text] [Related]
4. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848 [TBL] [Abstract][Full Text] [Related]
5. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Dahal K; Kunwar S; Rijal J; Schulman P; Lee J Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611 [TBL] [Abstract][Full Text] [Related]
6. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572 [TBL] [Abstract][Full Text] [Related]
8. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Chan PH; Huang D; Yip PS; Hai J; Tse HF; Chan TM; Lip GY; Lo WK; Siu CW Europace; 2016 May; 18(5):665-71. PubMed ID: 26504109 [TBL] [Abstract][Full Text] [Related]
9. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454 [TBL] [Abstract][Full Text] [Related]
10. Warfarin Use, Stroke, and Bleeding Risk among Pre-Existing Atrial Fibrillation US Veterans Transitioning to Dialysis. Sy J; Wenziger C; Marroquin M; Kalantar-Zadeh K; Kovesdy C; Streja E Nephron; 2022; 146(4):360-368. PubMed ID: 35124673 [TBL] [Abstract][Full Text] [Related]
11. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K; Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811 [TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and chronic kidney disease in Asian Population, Data from the COOL-AF Thailand registry. Chantrarat T; Krittayaphong R Int J Cardiol; 2021 Jan; 323():90-99. PubMed ID: 32828960 [TBL] [Abstract][Full Text] [Related]
13. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261 [TBL] [Abstract][Full Text] [Related]
14. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. Makani A; Saba S; Jain SK; Bhonsale A; Sharbaugh MS; Thoma F; Wang Y; Marroquin OC; Lee JS; Estes NAM; Mulukutla SR Am J Cardiol; 2020 Jan; 125(2):210-214. PubMed ID: 31780073 [TBL] [Abstract][Full Text] [Related]
16. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Arnson Y; Hoshen M; Berliner-Sendrey A; Reges O; Balicer R; Leibowitz M; Avgil Tsadok M; Haim M Cardiology; 2020; 145(3):178-186. PubMed ID: 31955174 [TBL] [Abstract][Full Text] [Related]
17. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. Su X; Yan B; Wang L; Lv J; Cheng H; Chen Y Am J Kidney Dis; 2021 Nov; 78(5):678-689.e1. PubMed ID: 33872690 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
19. Aortic Stenosis and Outcomes in Patients With Atrial Fibrillation: A Nationwide Cohort Study. Teppo K; Airaksinen KEJ; Biancari F; Jaakkola J; Halminen O; Linna M; Haukka J; Putaala J; Mustonen P; Kinnunen J; Luojus A; Hartikainen J; Aro AL; Lehto M J Am Heart Assoc; 2023 May; 12(9):e029337. PubMed ID: 37119067 [TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. Di Lullo L; Tripepi G; Ronco C; De Pascalis A; Barbera V; Granata A; Russo D; Di Iorio BR; Paoletti E; Ravera M; Fusaro M; Bellasi A J Nephrol; 2018 Oct; 31(5):751-756. PubMed ID: 29882198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]